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AcknowledgmentThe evolution of the modern sciences had lead to divers
amifications and to the emergence of new fields from the
nown classical sciences (Vermeulen et al., 2013). Yet, such
lassical sciences and the new emerging fields are still closely
elated due to the interactions they have with each other’s
nd the features they share which make mapping the links
etween them an important issue to both achieve more
dvances and eventually redefine the existing borders. Modern
esearch areas such as biological sciences and medicine are
mportant multidisciplinary fields for which both zoology
nd pharmacology play important roles in the advancement,
escription and applications of the new findings within novel
ontexts. Herein, common features and strong links can be
escribed between zoology and pharmacology.
Zoology, as a provider for data related to animal properties
nd species characteristic details, has been important for phar-
acology not only for drug animal experiments (De Wasch
t al., 2002) but also for cells (Jonsson et al., 2012; Braam
nd Mummery, 2010) and animal models (Spertzel and the
ublic Health Service Animal Models, 1989; Laurijssens
t al., 2013) for different pathways tests and pharmacological
tudies. Indeed, generally the first stage of active compounds
potential future drugs) studies is mainly to evaluate the effects
f the compounds on cell cultures (Ghanemi, 2014b), which
re mainly derived from animals especially in primary cultures,
r in vivo cell culture inside animal bodies such as rats.
urthermore, before we can move to the clinical trials, animal
xperiments are carried out to find out more elements about
he side effects, the toxicology (Ghanemi, 2014c) and define
ome parameters such as pharmacokinetic values. Moreover,
nimal behaviour and memory studies are extremely important
ainly for the study of some specific classes of drugs such as
sychotropic medicines and drugs used in the treatment of
eurodegenerative diseases, in addition, it allows us to under-
tand more about the psychiatric or psychological side effects
ome drugs (not only the psychotropic) may have. Impor-
antly, new finding, based on cell cultures and animal
esearches, have revealed important data about the G proteinAb
Pre
eer review under responsibility of The Egyptian German Society for
oology.
ttp://dx.doi.org/10.1016/S2090-9896(16)00021-7pled receptors that are among the most import
rapeutic targets in the modern pharmacology (Ghan
al., 2013; Ghanemi, 2013a, 2014d,e; Ghanemi a
ubertakh, 2014) which points the importance zoology
the recent pharmacological advances.
On the other hand, pharmacology that mainly focus
dying the effects that active compounds can have on
mal and human cells or entities such as enzym
labaster, 2002); represents an important tool for zoolo
the related fields such as the animal models of disea
r instance, the active drugs can be used in several zoolog
erimental processes. Some active molecules provided
er pharmacology or toxicology could be been used
elop animal models with specific characters and selec
tures to study diseases mechanisms or factors influe
example. In fact, for some disease we can have ma
tors that influence and thus, treating an animal with a d
t may eliminate the effect one factor has would allow us
dy that disease without the influence of that factor a
refore, lead to a better understanding of that dise
hogenesis or pathways.
These elements are selected examples that show h
logy and pharmacology are linked and how import
cribing the interactions between both fields could c
ute in the development of the two fields both at the exp
ental and at the theoretical level. Furthermore, combin
a provided by the related fields such as pharmacogn
hanemi and Boubertakh, 2014) especially by studying
perties of chemical (Ghanemi, 2014a,e) or natural produ
ubertakh et al., 2013; Phillipson, 2007) on cells, bioche
y (Ghanemi, 2013b) and cellular biology will surely be v
eficial to a better mapping of the bridges between zoolo
pharmacology toward deeper a understanding and furtdelaziz Ghanemi is the recipient of a 2013 CAS-TWAS
sident’s Postgraduate Fellowship.
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